WWTR1 and cancer: Pharmacological inhibition of YAP/TAZ, either through small molecules such as verteporfin, statins, or dasatinib, or via genetic approaches like CRISPR, represents a promising strategy for addressing Hippo pathway dysregulation in cancer.